ZyVersa Therapeutics, Inc.
ZVSA- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001859007
No open-market purchases or sales by ZyVersa Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding ZyVersa Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 4 | 6 | +2 |
| Shares | 10.3K | 3.06K | −7.24K (−70.3%) |
| Value | $38.7K | $7.22K | −$31.5K (−81.4%) |
New holders (3)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 433 | $1.04K | 0.00% |
| Morgan Stanley | 1 | $2 | 0.00% |
| Royal Bank of Canada | 52 | $0 | 0.00% |
Sold out (1)
Institutions that held ZyVersa Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| ADAR1 Capital Management, LLC | 9,598 | $36.1K |